8-K/A: FOXO Technologies Faces Delisting Threat After Missing NYSE Fee Payment Deadline

FOXO Technologies received a notice of noncompliance from the NYSE American due to unpaid listing fees, but has since made the required payments and is working to regain compliance.

Summary

• FOXO Technologies received a notice from the NYSE American stating they are not in compliance with continued listing standards due to unpaid listing fees that were over 180 days old.
• The company had until June 7, 2024, to pay the fees, but failed to do so.
• As a result, FOXO is now subject to delisting procedures.
• FOXO must submit a written response by June 17, 2024, outlining how they will pay the fees within 30 days.
• The company has since made the required payments and believes it is now in a position to regain compliance.
• There is no guarantee that FOXO will regain compliance with NYSE American listing standards.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the noncompliance notice and potential delisting, although the company has taken steps to rectify the situation. The uncertainty around regaining compliance and the mention of past losses contribute to the low score.

Positives

• FOXO has made the required payments after missing the initial deadline.
• The company intends to regain compliance with NYSE American listing standards.
• FOXO has contacted the NYSE to confirm receipt of the notice and indicate they plan to present a compliance plan.

Negatives

• FOXO failed to pay listing fees by the deadline, resulting in a noncompliance notice.
• The company is now subject to potential delisting procedures.
• There is no guarantee that FOXO will regain compliance with NYSE American listing standards.

Risks

• There is a risk that the NYSE may not accept FOXO's compliance plan.
• If the plan is not accepted or if FOXO does not make progress towards full payment, delisting proceedings will commence.
• The company's stock could be delisted from the NYSE American if they fail to regain compliance.
• The company has a history of losses and may not achieve or maintain profitability in the future.

Future Outlook

FOXO expects to formally regain compliance with the NYSE American continued listing standards in the near future, but there is no guarantee of this outcome.

Management Comments

• Mark White, Interim CEO of FOXO, stated that the delinquency was due to short-term capital allocation strategies.
• He also mentioned that the company has since made the payment and looks forward to formally presenting this to the NYSE American.

Industry Context

This announcement highlights the importance of maintaining compliance with exchange listing requirements, which is a common issue for companies, especially those in the biotechnology sector that may be facing financial challenges. It also shows the potential impact of short-term capital allocation strategies on a company's ability to meet its obligations.

Comparison to Industry Standards

• Many companies, especially smaller ones, face challenges in maintaining compliance with exchange listing requirements.
• The biotechnology industry is particularly susceptible to these issues due to the high costs of research and development and the long timeframes to commercialization.
• Other companies that have faced similar delisting threats include those with financial difficulties or those that have failed to meet minimum share price requirements.
• For example, companies like Cassava Sciences and Ocugen have faced scrutiny and potential delisting due to various issues, including compliance and financial concerns.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the stock price.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers and suppliers may also be concerned about the company's ability to continue operations.

Next Steps

• FOXO must submit a written response to the NYSE by June 17, 2024, outlining their plan to pay the outstanding fees.
• The company will need to work with the NYSE to ensure their compliance plan is accepted.
• FOXO will need to make progress towards full payment of all past-due fees.

Key Dates

Keywords

NYSE American, delisting, noncompliance, listing fees, compliance, FOXO Technologies, biotechnology